Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2016
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms Nilo Post-STIM
- 10 Jun 2017 Biomarkers information updated
- 19 Aug 2016 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 19 Aug 2016 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.